Skip to main content

Table 2 Univariate and multivariate analysis of TMEM176A methylation status with 3 year-overall survival (OS) in HCC patients

From: Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma

Clinical factor 3-year OS
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age 1.204 0.557   
 (< 60 vs. ≥ 60 years) (0.649–2.235)    
Gender 0.869 0.775   
 (Male vs. female) (0.331–2.282)    
TMEM176A 2.388 0.027* 2.370 0.025*
 (Methylation vs. unmethylation) (1.102–5.175)   (1.116–5.034)  
HBV infection 0.592 0.142   
  (YES vs. NO) (0.294–1.191)    
Liver cirrhosis 1.360 0.401   
 (Yes vs. no) (0.664–2.784)    
Tumor size 1.184 0.670   
 (≤ 5 cm vs. > 5 cm) (0.544–2.580)    
Number of lesions 0.902 0.793   
 (1 vs. ≥ 1) (0.419–1.944)    
Differentiation 2.212 0.020* 1.989 0.015*
 (Well or moderate vs. poor) (1.133–4.320)   (1.140–3.470)  
TNM stage 1.150 0.724   
 (Stage I + stage II vs. stage III + stage IV) (0.528–2.505)    
Lymph node metastasis 1.184 0.670   
 (Negative vs. positive) (0.544–2.580)    
Vessel cancerous embolus 0.444 0.025* 0.441 0.006**
 (Negative vs. positive) (0.219–0.902)   (0.245–0.794)  
  1. HR hazard ratio
  2. *P < 0.05; **P < 0.01